COMPANY OVERVIEW

We are a product focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA approved products. Our products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance.

History

Antares was formed in 2001 when Medi-Ject Corporation (a device company) merged with Permatec Holding AG (a developer of transdermal delivery systems). In the late 1970’s Medi-Ject was one of the first companies to develop reusable needle-free injection devices. Since that time costs have decreased and the technology has gained acceptance. Presently we have broad approval for our device in the US for insulin and in Europe, Asia and elsewhere for human growth hormone. We have recently added a disposable mini-needle product which uses a disposable single use small gauge needle for unit dose injectable drugs.

Prior to moving to Switzerland in 1999, Permatec was originally known for the estradiol patch, which was developed and marketed in Argentina. As next-generation products were invented and developed, the focus became transdermal gel delivery and fast-melt tablet technologies. Antares now also has a number of ATD™ gel products including products marketed in the US and Europe as well as products in clinical trials and development.
 

Operations

Antares operates in three locations: